Published in Hepatitis Weekly, August 6th, 2001
Furthermore, pretreatment values for liver activity, liver cancer markers, and platelet counts are predictive of post-treatment survival in patients who receive this therapy, according to medical investigators in Italy.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.